Ronald Martell describes Jasper's subcu programs for urticaria.

CEO Adrian Rawcliffe describes how Adaptimmune is preparing to launch what could be the first approved TCR based cell therapy in the U.S.

Emil Kakkis summarizes Ultragenyx's Angelman syndrome update at AAN and more.

Bill Sibold describes how Madrigal has prepared for the launch and illustrates how the medicine is meant to impact disease progression.

Darrin Miles describes how this molecular glue therapy has been designed to bind to MEK and all isoforms of MEK and RAF in combination.

EpicentRx CEO Tony Reid and MD Andersen investigator Anthony Conley describe TGF-β data presented at AACR.

She describes working with Steven Paul again, the Glyph technology that is the backbone of Seaport's platform, and more.

CEO Eamonn Hobbs describes the responses Syncromune is seeing in an early phase 1 prostate cancer study.

CEO Steven Kelly described the scientific basis of pipeline changes they have made this week and when we can expect to see data.

Bill Newell describes this week’s deal with Ipsen, the folate receptor alpha space, and more.

Co-Founder and CEO Eric Murphy describes what it was like raising the money in this environment.

CEO Lawrence Klein describes advances in antibody engineering Oruka is leveraing to make improved IL-23 and IL-17 inhibitors.

Sek Kathiresan describes what Verve believes caused elevated liver enzymes and thrombocytopenia in a PCSK9 gene editing trial.

Peter Maag describes how Kyverna has been focused on this area for five years.

Paul Hastings describes why Nkarta believes NK based therapies are uniquely fit for this area.

John Scarlett shares his take on imetelstat's clinical utility, potential commercial dynamics, the IP situation, and more.

Founder Mark McKenna describes the unmet need that exists in the I&I space.

Alexandria Forbes describes the investments MeiraGTx has made in manufacturing and how it is helped progress various programs.

David Campbell explains how Janux has used masking technology to improve the profile T-cell engagers in solid tumors.

Chris Varma describes why hitting KRAS G12C in both its on and off state could be an improvement over existing medicines.